Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025: Annex 1: Research proposal: V. Anticipated Outcomes

Comparative Analysis of National Drug Policies - Second Workshop Geneva, 10-13 June 1996 - EDM Research Series No. 025
(1997; 175 pages)

Table of Contents

Executive summary
I. Introduction
II. Background on the research project
	1. Research questions and objectives of the study
	2. Study approach and research tools
	3. Project past activities
III. Second workshop
	1. Aim and objectives
	2. Participants
	3. Method of work and proceedings
IV. Preliminary findings
	1. The methods: What has been learnt?
		1.1 Methods in context: How did the country teams use the methods?
		1.2 Methods in question: What were the main problems encountered and how to solve them?
		1.3 Relevance of the methods
	2. National drug policies: what has been learnt?
		2.1 Preliminary findings based on NDP indicators
		2.2 Preliminary interpretations based on NDP indicators
		2.3 Preliminary findings based on the political mapping
	3. Cross national analysis: What can be learnt at this stage?
		3.1 Relevance of the methods for cross national comparison
		3.2 Strengths and weaknesses of NDP from a cross national perspective
		3.3 Tentative explanations for cross national variations
	4. Broader capacity building
V. Conclusions of the workshop and follow-up plans
	1. Main outcomes
	2. Next steps
Annex 1: Research proposal
	I. Introduction
	II. The Problem
	III. Research Question and Objectives of Proposed Study
	IV. Study Approach
	V. Anticipated Outcomes
	VI. Methods
	VII. Time Line and Resources
	Selected References
Annex 2: List of participants
Annex 3: Agenda
Annex 4: Questionnaire on NDP performance assessment
Annex 5: Achievements of the national drug policies in the 12 countries
	Bulgaria
	Chad
	Colombia
	Guinea
	India
	Mali
	Philippines
	Sri Lanka
	Thailand
	Viet Nam
	Zambia
	Zimbabwe
Annex 6: Consolidated tables
Other documents in the DAP Research Series

V. Anticipated Outcomes

1. The project will apply a systematic cross-national method for the assessment of pharmaceutical policy performance, using summative and formative evaluation techniques, through the standardized indicators and the political mapping technique.

2. The assessment of pharmaceutical policy performance will provide the basis for generating hypotheses to explain how different pharmaceutical policies, especially different public/private mixes, can affect the performance of the pharmaceutical sector.

3. The project will assist policy-makers responsible for pharmaceutical policy in identifying and substantiating specific strengths and weaknesses of existing policy, from national and cross-national perspectives, and in formulating strategies to improve the implementation of pharmaceutical policy.

4. The project will provide field testing of the standard indicators and the political mapping technique in a series of countries, and their potential development into a method of policy analysis and rapid assessment of pharmaceutical sector performance.

5. The project will facilitate the collection of data for the WHO's forthcoming World Drug Situation Report.

6. The project will identify specific policy innovations from cross-national learning that could improve the design and implementation of pharmaceutical policy within each country, and will propose ways to improve the political feasibility of implementing those innovations within a specific political context.

7. The project will enhance the capacity of Essential National Health Research within each country, through the development and application of the policy performance assessment methodology and the political mapping methodology, both of which can be applied to other areas of health policy.

8. The project will provide an impetus for international agencies to reconsider their own policies for the pharmaceutical sector, and will assist in strengthening the policy analysis capabilities of international agencies involved in supporting the development of national pharmaceutical policy.